Ralliant Corporation Common Stock RAL 深 滬
等待開盤 12-15 09:30:00 美东时间
50.96
-1.260
-2.41%
華盛通- 最 高52.89
- 今 開52.89
- 成交量 104.69万股
- 最 低 50.56
- 昨 收 52.22
- 總市值 57.58亿
- 52周最高 54.50
- 市盈率 靜 16.20
- 換手率 0.00%
- 52周最低 40.65
- 委 比 2.27%
- 總股本 1.13亿
- 歷史最高 54.50
- 量 比 0.59
- 振 幅 4.46%
- 歷史最低 40.65
- 每 手 1
- 風險率 2.76%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 博通、Lululemon获10逾家大行上调目标价；好市多、RH遭大行下调目标价
今日重点评级关注：杰富瑞：维持ImmunityBio Inc Ordinary Shares"买入"评级，目标价从8美元升至9美元；B. Riley证券：维持WAVE Life Sciences"买入"评级，目标价从19美元升至37美元
今天 15:30
Shares of companies within the broader technology sector are trading lower amid weakness in Broadcom after it issued cautious outlook. The sector is also being weighed down by reports that Oracle delayed some data center projects for OpenAI.
Shares of companies within the broader technology sector are trading lower amid...
12-13 04:20
美股大行评级 | 潜在涨幅2566.67%！Ascendiant Capital上调GRI Bio目标价至36美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持GRI Bio"买入"评级，目标价从35美元升至36美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从7.75美元升至8美元
12-09 10:32
Citigroup Upgrades Ralliant to Buy, Raises Price Target to $61
Citigroup analyst Piyush Avasthy upgrades Ralliant (NYSE:RAL) from Neutral to Buy and raises the price target from $53 to $61.
12-08 22:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
RBC Capital Maintains Sector Perform on Ralliant, Raises Price Target to $52
RBC Capital analyst Deane Dray maintains Ralliant (NYSE:RAL) with a Sector Perform and raises the price target from $45 to $52.
11-08 03:25
Ralliant Q3 Adj. EPS $0.60 Beats $0.57 Estimate, Sales $529.100M Beat $521.049M Estimate
Ralliant (NYSE:RAL) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $0.57 by 4.71 percent. This is a 36.84 percent decrease over earnings of $0.95 per share from the same
11-06 06:17
Earnings Scheduled For November 5, 2025
Companies Reporting Before The Bell • Avient (NYSE:AVNT) is estimated to report...
11-05 19:12
First Citizens Names Erin McCaskill as New Wealth Leader in Atlanta
RALEIGH, N.C., Oct. 29, 2025 /PRNewswire/ -- First Citizens Wealth today announced the appointment of Erin McCaskill as Director and Atlanta Market Leader. Based in Atlanta, she reports to E...
10-29 20:30
